Zriza Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 11 Year, 17 Days
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 5.50 M
as on 23-12-2024
- Revenue -30.70%
(FY 2021)
- Profit -12.71%
(FY 2021)
- Ebitda 59.02%
(FY 2021)
- Net Worth 3.21%
(FY 2021)
- Total Assets 40.92%
(FY 2021)
About Zriza Pharmaceuticals
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.50 M.
Chethan Gangaiah and Papaiah Gangaiah serve as directors at the Company.
- CIN/LLPIN
U74900KA2013PTC072407
- Company No.
072407
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Dec 2013
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Zriza Pharmaceuticals Private Limited offer?
Zriza Pharmaceuticals Private Limited offers a wide range of products and services, including Body Care Products, Body Lotions, Hair Care Cosmetics, Hair Serum, Face Wash, Foam Face Wash, Cosmetics, Hair & Beauty Products, Skin Care Cosmetics, Eye Cosmetic, Eye Cream.
Who are the key members and board of directors at Zriza Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chethan Gangaiah  | Director | 09-Dec-2013 | Current |
| Papaiah Gangaiah | Director | 13-Nov-2014 | Current |
Financial Performance of Zriza Pharmaceuticals.
Zriza Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 30.7% decrease. The company also saw a substantial fall in profitability, with a 12.71% decrease in profit. The company's net worth moved up by a moderate rise of 3.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zriza Pharmaceuticals?
In 2021, Zriza Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Apr 2016 | ₹4.00 M | Open |
Others Creation Date: 28 Mar 2016 | ₹1.50 M | Open |
How Many Employees Work at Zriza Pharmaceuticals?
Unlock and access historical data on people associated with Zriza Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zriza Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zriza Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
